- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00338767
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
Depression Treatment to Improve Antiretroviral Adherence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Antiretroviral drug therapy (ART) is a type of medication treatment for HIV that impairs the virus's ability to multiply. When used properly, it has been shown to be successful in reducing HIV-related deaths. A 95% adherence rate to ART is required to adequately suppress the virus and prevent transmission. Low ART adherence rates are often linked to depression, which is especially common in HIV-infected homeless or marginally housed people. In these cases, treatment with antidepressant medication may be useful in improving ART adherence. Directly Observed Therapy (DOT), in which medication intake is closely monitored, is another method of enhancing treatment compliance. DOT improved treatment adherence during the tuberculosis epidemic of the 1990s, and is now gaining recognition as a model for improving ART adherence. This study will evaluate the effectiveness of combining DOT and antidepressant medication in improving ART adherence among HIV-infected homeless and marginally housed people with depression.
Participants in this 9-month, open-label study will be randomly assigned to a treatment group or a control group. The control group will be given the phone number of the University of California, San Francisco AIDS Health Project (AHP) to call and make an appointment with a psychiatrist. Participants who attend appointments will be evaluated to determine their mental health status. Participants who are deemed to benefit from treatment will be scheduled for regular appointments at the AHP, but will be responsible for administering their own medications. The treatment group will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen. If an individual does not attend a visit, study staff will try to locate the individual in the neighborhood to deliver the medication. Medication for the weekend will be prepared by study staff, but participants will take it on their own at home. For the last 2 months of the study, DOT visits will occur once monthly, at which time participants will receive their entire month's supply of medication.
Participants in both groups will be asked to report to the study site weekly for 6 months and then monthly for the final 3 months to provide an update on the status of their housing, healthcare providers, case managers, and HIV medications. Additional interviews about housing, income, use of health services, drug use, sexual practices, and mental health will occur at the beginning of the study and three more times throughout the study. Blood tests will be performed monthly to assess viral load, and every 3 months to assess CD4 count. Participants taking HIV medications will be visited by study staff at home once a month so that use of HIV medications can be determined. At the end of the study, participants in the control group may continue receiving treatment at the AHP. Six months after the end of the study, participants in the treatment group may also begin treatment with a psychiatrist at the AHP.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94102
- UCSF Market Street Study Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Homeless or marginally housed
- Score of greater than 13 on the Beck Depression Inventory (BDI)
- DSM-IV diagnosis of major depressive disorder, dysthymia, or minor depressive disorder
- Considered by the reviewing psychiatrist to benefit from antidepressant therapy
- Willing to take antidepressant medication or, if currently taking medication, willing to change medications if deemed appropriate
- Consents to coordinate with the primary medical provider
- Speaks English
Exclusion Criteria:
- Signs and symptoms consistent with diagnosis of dementia, as defined by DSM-IV
- Current substance abuse disorder requiring immediate residential or inpatient treatment
- At risk for suicide
- Presence of signs and symptoms consistent with psychotic depression, as defined by DSM-IV, warranting immediate hospitalization
- Any condition or use of any medication that may make simultaneous use of antidepressant medication unsafe
- Currently prescribed antidepressant therapy and in psychiatric treatment (treated by a psychiatrist within 3 months prior to study entry)
- Pregnant
- Bipolar disorder
- Current psychotic disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
|
DOT includes storefront directly observed therapy of prescribed anti-depressants.
Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication.
Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study.
Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications.
After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
Medication treatment includes flouxetine for treatment of depression.
|
No Intervention: Control
Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improved depression scores
Time Frame: Measured at the end of 9 months
|
Measured at the end of 9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HIV viral load
Time Frame: Measured monthly for 9 months
|
Measured monthly for 9 months
|
CD4 Count
Time Frame: Measured at baseline and Months 3, 6, and 9
|
Measured at baseline and Months 3, 6, and 9
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David R. Bangsberg, MD, MPH, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Depression
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Fluoxetine
Other Study ID Numbers
- R01MH063011 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Directly Observed Therapy (DOT)
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA); Gilead Sciences; Denver Health and Hospital...CompletedVirus, Human Immunodeficiency | HEPATITIS CUnited States
-
University of BamakoUnknown
-
Johns Hopkins UniversityUniversity of Cape TownTerminated
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
UConn HealthTerminatedDepressionUnited States
-
University of California, San DiegoCompletedTuberculosis | Latent Tuberculosis InfectionUnited States
-
Oslo University HospitalCompleted
-
Mattienne van der KampNot yet recruiting